Imidazo[1,2-a]Pyridin-3-Amine, N-(2,3-Dihydro-1,4-Benzodioxin-6-yl)-2-(2-Furanyl)-; N-(2,3-Dihydro-1,4-Benzodioxin-6-yl)-2-(2-Furyl)Imidazo[1,2-a]Pyridin-3-Amine

Brief Introduction

Dulaglutide is a glucagon like peptide-1 (GLP-1) receptor agonist.

Fostamatinib Disodium Hexahydrate

CAS:914295-16-2

Molecular Formula:C23H24FN6Na2O9P

Alias

More Information

Fostamatinibdisodiumhexahydrate; 6-[[5-Fluoro-2-[(3,4,5-Trimethoxyphenyl)Amino]-4-Pyrimidinyl]Amino]-2,2-Dimethyl-4-[(Phosphonooxy)Methyl]-2H-Pyrido[3,2-b]-1,4-Oxazin-3(4H)-Onedisodiumsalthexahydrate; Fostamatinibdisodiumsalthexahydrate; 6-[[5-Fluoro-2-[(3,4,5-Trimethoxyphenyl)Amino]-4-Pyrimidinyl]Amino]-2,2-Dimethyl-4-[(Phosphonooxy)Methyl]-2H-Pyrido[3,2-b]-1,4-Oxazin-3(4H)-Onesodiumsalthydrate;R788(Disodiumhexahydrate); Fostamatinibna; 2H-Pyrido[3,2-b]-1,4-Oxazin-3(4H)-one,6-[[5-Fluoro-2-[(3,4,5-Trimethoxyphenyl)Amino]-4-Pyrimidinyl]Amino]-2,2-Dimethyl-4-[(Phosphonooxy)Methyl]-,Disodiumsalt,Hexahydrate; R788Disodiumhexahydrate(Fostamatinibdisodiumhexahydrate); ; R788 Disodium Hexahydrate; R788 (Disodium Hexahydrate); 2H-Pyrido[3,2-b]-1,4-Oxazin-3(4H)-one, 6-[[5-Fluoro-2-[(3,4,5-Trimethoxyphenyl)Amino]-4-Pyrimidinyl]Amino]-2,2-Dimethyl-4-[(Phosphonooxy)Methyl]-, Disodium salt, Hexahydrate

Brief Introduction

Fostamatinib Disodium Hexahydrate is a white powdery substance that can be used as a pharmaceutical raw material.

Enrofloxacin Base

Alias

More Information

Enroflxacin

Diquafosol Tetrasodium

CAS:211427-08-6

Molecular Formula:C18H27N4NaO23P4

Alias

More Information

INS365; D03864; Diquafosolsodium; Diquafosolsodium(jan); Diquafosoltetrasodium; Diquafosoltetrasodium(usan); Diquafosolimpurity7(UP4U); [[(2R,3S,4R,5R)-5-(2,4-Dioxopyrimidin-1-yl)-3,4-Dihydroxyoxolan-2-yl]Methoxy-Oxidophosphoryl][[[(2R,3S,4R,5R)-5-(2,4-Dioxopyrimidin-1-yl)-3,4-Dihydroxyoxolan-2-yl]Methoxy-Oxidophosphoryl]oxy-Oxidophosphoryl]Phosphate

Brief Introduction

Diquafosol Tetrasodium (Diquafosol Tetrasodium Tetrasodium), chemically known as P1,P4-di(uridine 5'-tetrahydrogen tetraphosphate) sodium, was jointly developed by Santen Pharmaceuticals, Inc. and Inspire Pharmaceuticals, Inc. and was launched in Japan in 2010 under the trade name Diquas, and Diquafosol Tetrasodium Eye Drops had sales of approximately $100 million in 2017 . Diquafosol Tetrasodium Eye Drops is the first P2Y2 receptor agonist eye drops approved for marketing in the world, which acts on the P2Y2 receptor on the conjunctival epithelium and cuprocyte membranes to improve the symptoms of dry eye disease by up-regulating the concentration of intracellular calcium ions, and promoting the secretion of water and mucin, thus bringing the tear film closer to its normal state. In addition, Diquafosol Tetrasodium Eye Drops is a compound expected to be developed as a depyritizing agent with phlegm-inducing effects or as a therapeutic agent for pneumonia.

Inquiry (

/ 10

)

Clear All